Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
What is the purpose of this trial?
Cumberland Pharmaceuticals Inc. (CPI) is developing ifetroban for treatment of hepatorenal syndrome (HRS) and proposes to conduct a study in hospitalized adult patients with HRS to assess the safety and pharmacokinetics of escalating doses of ifetroban.
- 18 Years and older
- Cumberland Pharmaceuticals
- October 2011
- Last Updated:
- January 25, 2013
- Study HIC#:
Clinicaltrials.gov ID: NCT01436500